Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby’s body temperature—called therapeutic hypothermia—is often used ...

Many infants with mild neonatal encephalopathy face long-term disabilities, highlighting the need for evidence-based treatments such as therapeutic cooling Mild neonatal encephalopathy is determined ...

Adding a high dose of erythropoietin to therapeutic hypothermia did not reduce rates of death or disability in infants with neonatal hypoxic ischemic encephalopathy (HIE), a phase III randomized trial ...

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune ...